Peptide derived from HIV-1gag p17, antigen comprising the peptide and use thereof, vaccine composition, antibody, nucleic acid, expression vector and host cell
Described is modified peptide capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptide is based on conserved regions of HIV gag p17 proteins. Described are antigens in free- or carrier-bound form comprising said peptide, vaccine compositions containing the antigen, their use, their antigens, a nucleic acid coding the peptide, an expression vector comprising the nucleic acid and a host cell comprising the expression vector.Described is modified peptide capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptide is based on conserved regions of HIV gag p17 proteins. Described are antigens in free- or carrier-bound form comprising said peptide, vaccine compositions containing the antigen, their use, their antigens, a nucleic acid coding the peptide, an expression vector comprising the nucleic acid and a host cell comprising the expression vector.
